Related Experiment Video
Updated: Mar 24, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
28.0K
Minimal change disease onset observed after bevacizumab administration
Ramy M Hanna1, Eduardo Lopez2, James Wilson3
1Department of Medicine, Division of Nephrology, Cedars Sinai Medical Center-Office Towers, Los Angeles, CA, USA.
Clinical Kidney Journal
|March 18, 2016
Summary
Minimal change disease (MCD) can rarely occur after bevacizumab treatment for brain tumors. Prompt steroid treatment resolved the nephrotic syndrome in this patient.
Area of Science:
- Nephrology
- Oncology
- Pathology
Background:
- Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, is used in cancer therapy.
- Temozolomide combined with bevacizumab is a treatment option for inoperable Grade 3 astrocytoma.
Observation:
- A 72-year-old male patient developed nephrotic syndrome after two biweekly treatments with bevacizumab and temozolomide.
- Renal biopsy confirmed minimal change disease (MCD) following bevacizumab administration, despite drug cessation.
Findings:
- High-dose oral prednisone therapy led to immediate improvement in renal function.
- The patient's nephrotic syndrome resolved within weeks of initiating steroid treatment.
Implications:
- This case highlights a rare but significant adverse effect of bevacizumab, specifically drug-induced glomerulopathy.
- Minimal change disease should be considered in patients presenting with nephrotic syndrome during treatment with antiangiogenic agents like bevacizumab.
- Awareness of this potential complication is crucial for timely diagnosis and management in oncology patients.
More Related Videos
Related Concept Videos
01:29Therapeutic Drug Monitoring: Affecting Factors
323
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
323
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
334
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
334
02:07Tumor Progression
7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K